• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Subsequent therapy following pembrolizumab plus axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncGafanov.pdf
    Size:
    97.71Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Gafanov, R.
    Powles, T. B.
    Bedke, J.
    Stus, V.
    Waddell, Thomas
    Nosov, D.
    Pouliot, F.
    Soulieres, D.
    Melichar, B.
    Azevedo, S.
    McDermott, R. S.
    Vynnychenko, I. O.
    Borchiellini, D.
    Markus, M.
    Bondarenko, I.
    Lin, J.
    Burgents, J.
    Molife, L. R.
    Plimack, E. R.
    Rini, B.
    Show allShow less
    Affiliation
    Urology, Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federa-tion;
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background:In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showedsignificant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. Thisanalysis assessed subsequent treatment in patients enrolled in KEYNOTE-426.Methods:Treatment-naive patients with clear cell RCC, KPS score =70%, andmeasurable disease (RECIST v1.1) were randomly assigned 1:1 to receive pem-brolizumab 200 mg IV every 3 weeks for up to 35 doses + axitinib 5 mg orally twicedaily or sunitinib 50 mg once daily (4 weeks on/2 weeks off) until progression, toxicity,or withdrawal. Type of and time to subsequent therapy were assessed.Results:Of patients in the pembrolizumab + axitinib arm and in the sunitinib arm,81.4% (349/432) and 90.6% of patients (385/429), respectively, discontinued treat-ment; radiologic or clinical PD was the most common reason for discontinuation inboth (pembrolizumab + axitinib: 65.0% [227/349]; sunitinib: 68.1% [262/385]). Ofpatients who discontinued, 58.5% of patients (204/349) in the pembrolizumab +axitinib arm and 73.0% (281/385) in the sunitinib arm received subsequent therapy(Table). Although a similar proportion of patients in both arms received subsequenttherapy with a VEGF/VEGFR inhibitor (pembrolizumab + axitinib: 88.2% [180/204];sunitinib: 68.7% [193/281]), a greater proportion of patients in the sunitinib arm(74.4% [209/281]) received subsequent PD-1/PD-L1 inhibitor therapy than in thepembrolizumab + axitinib arm (21.6% [44/204]). Of patients in the pembrolizumab +axitinib arm and the sunitinib arm, 32.4% (66/204) and 22.8% (64/281), respectively,received other therapies.Conclusions:The superior efficacy of pembrolizumab + axitinib compared withsunitinib is observed despite the increased use of subsequent therapy in the sunitinibarm. These data continue to support the use offirst-line pembrolizumab + axitinib in patients with RCC
    Citation
    Gafanov R, Powles TB, Bedke J, Stus V, Waddell TS, Nosov D, et al. 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S694.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624711
    DOI
    10.1016/j.annonc.2021.08.065
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.065
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.065
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.